Physician profile
Azarel Abinader
NPI 1942388566
$15,619.82
in general payments reported to CMS, 2019-2025
40 companies · $6,087 in 2025
The $6,087 reported for 2025 was more than what 87% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $1,965 · 2020: $1,130 · 2021: $213 · 2023: $2,087 · 2024: $4,138 · 2025: $6,087.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,522 · Travel and Lodging: $3,697 · Education: $92.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,521.64 |
| Travel and Lodging | $3,697.08 |
| Education | $92.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,494.75 | 2019-2025 | Cosentyx |
| Argenx US, INC. | $1,926.57 | 2025 | Vyvgart Hytrulo |
| Abbvie INC. | $1,426.31 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Amgen INC. | $969.93 | 2019-2025 | Enbrel, Otezla, Evenity |
| Ucb, INC. | $787.58 | 2019-2025 | Cimzia, Bimzelx |
| Ani Pharmaceuticals, INC. | $755.95 | 2023-2025 | Purified Cortrophin Gel |
| Glaxosmithkline, LLC. | $655.94 | 2019-2025 | Benlysta, Nucala |
| Mallinckrodt Hospital Products INC. | $648.23 | 2023-2025 | Acthar |
| Radius Health, INC. | $641.16 | 2019-2025 | Tymlos |
| Genzyme Corporation | $548.73 | 2019-2025 | |
| Janssen Biotech, INC. | $525.01 | 2019-2025 | Tremfya, Simponi Aria |
| E.R. Squibb & Sons, L.L.C. | $472.41 | 2019-2025 | Orencia |
| Astrazeneca Pharmaceuticals LP | $467.94 | 2023-2025 | Saphnelo |
| Lilly USA, LLC | $456.29 | 2019-2020 | |
| Pfizer INC. | $380.90 | 2019-2025 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $203.61 | 2019 | |
| Horizon Therapeutics Plc | $191.37 | 2020-2023 | Krystexxa |
| Alvogen INC | $143.78 | 2024-2025 | Teriparatide |
| Aurinia Pharma U.S., INC. | $133.64 | 2023-2025 | Lupkynis |
| Sanofi-Aventis U.S. LLC | $85.84 | 2019-2020 | |
| Csl Behring | $72.23 | 2025 | Andembry, Haegarda |
| Sobi, INC | $72.20 | 2019-2024 | |
| Neurometrix INC | $68.62 | 2023 | |
| Ferring Pharmaceuticals INC. | $64.73 | 2019 | |
| Sandoz INC. | $53.05 | 2025 | Hyrimoz, Jubbonti |
| Organon LLC | $40.88 | 2023-2024 | Hadlima |
| Octapharma USA, INC. | $37.37 | 2023-2024 | Octagam Immune Globulin (Human) |
| Relievant Medsystems, INC. | $30.30 | 2023 | Intracept |
| Viiv Healthcare Company | $25.22 | 2025 | Apretude |
| Fidia Pharma USA INC. | $24.61 | 2019 | |
| Medexus Pharma, INC. | $24.37 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.81 | 2025 | Ofev |
| Takeda Pharmaceuticals U.S.A., INC. | $23.66 | 2025 | Takhzyro |
| Grifols USA, LLC | $23.40 | 2025 | Gamunex-C |
| Depuy Synthes Sales INC. | $23.29 | 2023 | Orthovisc |
| Hikma Pharmaceuticals USA | $23.16 | 2019 | |
| Pharming Healthcare, INC. | $21.77 | 2024 | Ruconest |
| Kyowa Kirin, INC. | $19.57 | 2023 | Crysvita |
| Fresenius Kabi USA, LLC | $17.93 | 2024 | Idacio |
| Kiniksa Pharmaceuticals International, Plc | $13.71 | 2024 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,620.13 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Azarel Abinader listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.